Cargando…

Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer

Aberrant factors associated with fibrinolysis and thrombosis are found in many cancer patients, which can promote metastasis and are associated with poor prognosis. The relationship between tumor-associated fibrinolysis and thrombosis is poorly understood in pancreatic cancer. This review provides a...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Lianghua, Xu, Qing, Qian, Jun, Zhou, Jin-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797325/
https://www.ncbi.nlm.nih.gov/pubmed/33442266
http://dx.doi.org/10.2147/OTT.S281251
_version_ 1783634843820621824
author Fang, Lianghua
Xu, Qing
Qian, Jun
Zhou, Jin-Yong
author_facet Fang, Lianghua
Xu, Qing
Qian, Jun
Zhou, Jin-Yong
author_sort Fang, Lianghua
collection PubMed
description Aberrant factors associated with fibrinolysis and thrombosis are found in many cancer patients, which can promote metastasis and are associated with poor prognosis. The relationship between tumor-associated fibrinolysis and thrombosis is poorly understood in pancreatic cancer. This review provides a brief highlight of existing studies that the fibrinolysis and coagulation systems were activated in pancreatic cancer patients, along with aberrant high concentrations of tissue plasminogen activator (t-PA), urine plasminogen activator (u-PA), D-dimer, fibrinogen, or platelets. These factors cooperate with each other, propelling tumor cell shedding, localization, adhesion to distant metastasis. The relationship between thrombosis or fibrinolysis and cancer immune escape is also investigated. In addition, the potential prevention and therapy strategies of pancreatic cancer targeting factors in fibrinolysis and coagulation systems are also been discussed, in which we highlight two effective agents aspirin and low-molecular weight heparin (LMWH). Summarily, this review provides new directions for the research and treatment of pancreatic cancer.
format Online
Article
Text
id pubmed-7797325
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-77973252021-01-12 Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer Fang, Lianghua Xu, Qing Qian, Jun Zhou, Jin-Yong Onco Targets Ther Review Aberrant factors associated with fibrinolysis and thrombosis are found in many cancer patients, which can promote metastasis and are associated with poor prognosis. The relationship between tumor-associated fibrinolysis and thrombosis is poorly understood in pancreatic cancer. This review provides a brief highlight of existing studies that the fibrinolysis and coagulation systems were activated in pancreatic cancer patients, along with aberrant high concentrations of tissue plasminogen activator (t-PA), urine plasminogen activator (u-PA), D-dimer, fibrinogen, or platelets. These factors cooperate with each other, propelling tumor cell shedding, localization, adhesion to distant metastasis. The relationship between thrombosis or fibrinolysis and cancer immune escape is also investigated. In addition, the potential prevention and therapy strategies of pancreatic cancer targeting factors in fibrinolysis and coagulation systems are also been discussed, in which we highlight two effective agents aspirin and low-molecular weight heparin (LMWH). Summarily, this review provides new directions for the research and treatment of pancreatic cancer. Dove 2021-01-06 /pmc/articles/PMC7797325/ /pubmed/33442266 http://dx.doi.org/10.2147/OTT.S281251 Text en © 2021 Fang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Fang, Lianghua
Xu, Qing
Qian, Jun
Zhou, Jin-Yong
Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer
title Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer
title_full Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer
title_fullStr Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer
title_full_unstemmed Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer
title_short Aberrant Factors of Fibrinolysis and Coagulation in Pancreatic Cancer
title_sort aberrant factors of fibrinolysis and coagulation in pancreatic cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7797325/
https://www.ncbi.nlm.nih.gov/pubmed/33442266
http://dx.doi.org/10.2147/OTT.S281251
work_keys_str_mv AT fanglianghua aberrantfactorsoffibrinolysisandcoagulationinpancreaticcancer
AT xuqing aberrantfactorsoffibrinolysisandcoagulationinpancreaticcancer
AT qianjun aberrantfactorsoffibrinolysisandcoagulationinpancreaticcancer
AT zhoujinyong aberrantfactorsoffibrinolysisandcoagulationinpancreaticcancer